These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35508762)

  • 1. Absorption, metabolism and excretion of opicapone in human healthy volunteers.
    Loureiro AI; Rocha F; Santos AT; Singh N; Bonifácio MJ; Pinto R; Kiss LE; Soares-da-Silva P
    Br J Clin Pharmacol; 2022 Oct; 88(10):4540-4551. PubMed ID: 35508762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.
    Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Sousa F; Kiss LE; Soares-da-Silva P
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00891. PubMed ID: 34939338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.
    Jorga K; Fotteler B; Heizmann P; Gasser R
    Br J Clin Pharmacol; 1999 Oct; 48(4):513-20. PubMed ID: 10583021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.
    Rocha JF; Almeida L; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
    Br J Clin Pharmacol; 2013 Nov; 76(5):763-75. PubMed ID: 23336248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.
    Almeida L; Rocha JF; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
    Clin Pharmacokinet; 2013 Feb; 52(2):139-51. PubMed ID: 23248072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.
    Gonçalves D; Alves G; Fortuna A; Bonifácio MJ; Soares-da-Silva P; Falcão A
    Neuropharmacology; 2017 Oct; 125():146-155. PubMed ID: 28734868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
    Kitajima T; Mizote S; Bonifácio MJ; Umemura T; Yoneda K; Moser P; Soares-da-Silva P; Tanaka M
    Neuropharmacology; 2018 Dec; 143():282-288. PubMed ID: 30290160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.
    Gonçalves D; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Toxicol Appl Pharmacol; 2017 May; 323():9-15. PubMed ID: 28322896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study.
    Pinto R; l'Hostis P; Patat A; Homery MC; Falcão A; Nunes T; Rocha JF; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):454-62. PubMed ID: 27137718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Opicapone and Its Metabolites in Healthy White and Chinese Subjects.
    Xue W; Tan Y; Liu Y; Xu C; Cong D; Zhong L; Song J; Hui A; Qi W; Wang J; Liu X; Li K
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1316-1324. PubMed ID: 33864709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects.
    Falcão A; Rocha JF; Santos A; Nunes T; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):150-61. PubMed ID: 27138028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion balance and pharmacokinetics following a single oral dose of [
    Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers.
    Toda R; Miyagawa T; Masuda Y; Hoshino Y; Yoshii K; Hirayama M; Shibuya M; Kawabata Y
    Xenobiotica; 2018 Oct; 48(10):1006-1020. PubMed ID: 29092680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
    Tiseo PJ; Perdomo CA; Friedhoff LT
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.